Palo Alto Investors’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-19,800
| Closed | -$682K | – | 46 |
|
|
2020
Q3 | $682K | Sell |
19,800
-3,298,412
| -99% | -$70.2M | 0.04% | 38 |
|
|
2020
Q2 | $55.4M | Buy |
3,318,212
+22,500
| +0.7% | +$382K | 3.33% | 11 |
|
|
2020
Q1 | $47.5M | Sell |
3,295,712
-84,729
| -3% | -$2.17M | 3.98% | 12 |
|
|
2019
Q4 | $113M | Sell |
3,380,441
-91,299
| -3% | -$2.55M | 6.23% | 7 |
|
|
2019
Q3 | $72.7M | Sell |
3,471,740
-356,824
| -9% | -$7.28M | 4.84% | 10 |
|
|
2019
Q2 | $79.7M | Buy |
3,828,564
+79,625
| +2% | +$1.64M | 3.88% | 12 |
|
|
2019
Q1 | $83.8M | Buy |
3,748,939
+2,361,350
| +170% | +$55.6M | 3.5% | 14 |
|
|
2018
Q4 | $33.2M | Buy |
1,387,589
+5,830
| +0.4% | +$151K | 1.77% | 17 |
|
|
2018
Q3 | $37.7M | Hold |
1,381,759
| – | – | 1.52% | 19 |
|
|
2018
Q2 | $37.2M | Buy |
1,381,759
+25,245
| +2% | +$773K | 1.48% | 18 |
|
|
2018
Q1 | $43.2M | Buy |
1,356,514
+210,095
| +18% | +$7.39M | 1.85% | 17 |
|
|
2017
Q4 | $43.4M | Sell |
1,146,419
-147,345
| -11% | -$4.75M | 1.87% | 17 |
|
|
2017
Q3 | $32.1M | Buy |
1,293,764
+4,045
| +0.3% | +$87.2K | 1.35% | 21 |
|
|
2017
Q2 | $26.5M | Buy |
1,289,719
+116,221
| +10% | +$2.22M | 1.24% | 21 |
|
|
2017
Q1 | $25.5M | Buy |
1,173,498
+793,771
| +209% | +$16.3M | 1.21% | 20 |
|
|
2016
Q4 | $7.76M | Hold |
379,727
| – | – | 0.44% | 24 |
|
|
2016
Q3 | $5.7M | Buy |
379,727
+54,128
| +17% | +$731K | 0.33% | 28 |
|
|
2016
Q2 | $3.52M | Hold |
325,599
| – | – | 0.27% | 33 |
|
|
2016
Q1 | $4.42M | Hold |
325,599
| – | – | 0.34% | 29 |
|
|
2015
Q4 | $6.01M | Hold |
325,599
| – | – | 0.33% | 29 |
|
|
2015
Q3 | $8.24M | Buy |
+325,599
| New | +$7.61M | 0.4% | 29 |
|
Palo Alto Investors's AIMT Position: Q4 2020 in Review
Palo Alto Investors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 19,800 shares — an estimated $682K sold.
Palo Alto Investors first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $113M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Palo Alto Investors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Palo Alto Investors sold 19,800 Aimmune Therapeutics shares in Q4 2020, an estimated $682K.
- Palo Alto Investors first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- Palo Alto Investors's Aimmune Therapeutics position peaked at $113M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Palo Alto Investors's 13F filing for Q4 2020, filed 16 Feb 2021.